QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Announces Completion of Manufacturing of Lead Drug Candidate
CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the central nervous system, has completed the manufacturing process for Berubicin Drug Product. CNSP’s U.S. manufacturer, Pharmaceutics International Inc. ("Pii"), has finished manufacturing the drug, which is the company’s lead drug candidate for the treatment of glioblastoma multiforme (“GBM”), an aggressive form of incurable brain cancer. In an attempt to diversify its supply chain, provide for local accessibility of Berubicin and reduce COVID-19-related delay risks, CNS had implemented a dual-track drug product manufacturing approach that used two different manufacturers for…